Masahiko Mori1,2, Ellen Leitman1, Bruce Walker3, Thumbi Ndung'u3,4,5,6, Mary Carrington3,7, Philip Goulder1,4. 1. Department of Paediatrics, University of Oxford. 2. Department of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, Japan. 3. Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge. 4. HIV Pathogenesis Programme, Doris Duke Medical Research Institute, University of KwaZulu-Natal. 5. Africa Health Research Institute, Durban, South Africa. 6. Max Planck Institute for Infection Biology, Berlin, Germany. 7. Cancer and Inflammation Program, Frederick National Laboratory for Cancer Research, Maryland.
Abstract
BACKGROUND: HLA class I contributes to HIV immune control through antigen presentation to cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. In contrast to investigations of CTL, studies of NK cells in HIV control through HLA-killer immunoglobulin-like receptor (KIR) interactions remain sparse in African cohorts. METHODS: Treatment-naive, chronically HIV-infected adults (N = 312) were recruited from South Africa, and the effects of HLA-KIR pairs on clinical outcome were analyzed. RESULTS: There was no significant difference in viral load among all subjects with HLA alleles from the HLA-C1 group (P = .1). However, differences in HLA-C type significantly influenced viremia among 247 KIR2DL3 positives (P = .04), suggesting that specific HLA-KIR interactions contribute to immune control. Higher viral load (P = .02) and lower CD4+ T-cell counts (P = .008) were observed in subjects with HLA-C*16:01+KIR2DL3+. Longitudinal analysis showed more rapid progression to AIDS among HLA-C*16:01+KIR2DL3+ subjects (adjusted hazard ratio 1.9, P = .03) than those without this genotype, independent of CD4+ T-cell count and viral load. CONCLUSIONS: These results highlight the existence of unique anti-HIV innate immunity within distinct populations and the contribution of KIR on NK cells and some CTLs to the well-described HLA-mediated impact on HIV disease progression.
BACKGROUND: HLA class I contributes to HIV immune control through antigen presentation to cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. In contrast to investigations of CTL, studies of NK cells in HIV control through HLA-killer immunoglobulin-like receptor (KIR) interactions remain sparse in African cohorts. METHODS: Treatment-naive, chronically HIV-infected adults (N = 312) were recruited from South Africa, and the effects of HLA-KIR pairs on clinical outcome were analyzed. RESULTS: There was no significant difference in viral load among all subjects with HLA alleles from the HLA-C1 group (P = .1). However, differences in HLA-C type significantly influenced viremia among 247 KIR2DL3 positives (P = .04), suggesting that specific HLA-KIR interactions contribute to immune control. Higher viral load (P = .02) and lower CD4+ T-cell counts (P = .008) were observed in subjects with HLA-C*16:01+KIR2DL3+. Longitudinal analysis showed more rapid progression to AIDS among HLA-C*16:01+KIR2DL3+ subjects (adjusted hazard ratio 1.9, P = .03) than those without this genotype, independent of CD4+ T-cell count and viral load. CONCLUSIONS: These results highlight the existence of unique anti-HIV innate immunity within distinct populations and the contribution of KIR on NK cells and some CTLs to the well-described HLA-mediated impact on HIV disease progression.
Authors: Photini Kiepiela; Kholiswa Ngumbela; Christina Thobakgale; Dhanwanthie Ramduth; Isobella Honeyborne; Eshia Moodley; Shabashini Reddy; Chantal de Pierres; Zenele Mncube; Nompumelelo Mkhwanazi; Karen Bishop; Mary van der Stok; Kriebashnie Nair; Nasreen Khan; Hayley Crawford; Rebecca Payne; Alasdair Leslie; Julia Prado; Andrew Prendergast; John Frater; Noel McCarthy; Christian Brander; Gerald H Learn; David Nickle; Christine Rousseau; Hoosen Coovadia; James I Mullins; David Heckerman; Bruce D Walker; Philip Goulder Journal: Nat Med Date: 2006-12-17 Impact factor: 53.440
Authors: O Mandelboim; H T Reyburn; M Valés-Gómez; L Pazmany; M Colonna; G Borsellino; J L Strominger Journal: J Exp Med Date: 1996-09-01 Impact factor: 14.307
Authors: Faviel F González-Galarza; Louise Y C Takeshita; Eduardo J M Santos; Felicity Kempson; Maria Helena Thomaz Maia; Andrea Luciana Soares da Silva; André Luiz Teles e Silva; Gurpreet S Ghattaoraya; Ana Alfirevic; Andrew R Jones; Derek Middleton Journal: Nucleic Acids Res Date: 2014-11-20 Impact factor: 19.160
Authors: Angelique Hölzemer; Christina F Thobakgale; Camilo A Jimenez Cruz; Wilfredo F Garcia-Beltran; Jonathan M Carlson; Nienke H van Teijlingen; Jaclyn K Mann; Manjeetha Jaggernath; Seung-gu Kang; Christian Körner; Amy W Chung; Jamie L Schafer; David T Evans; Galit Alter; Bruce D Walker; Philip J Goulder; Mary Carrington; Pia Hartmann; Thomas Pertel; Ruhong Zhou; Thumbi Ndung'u; Marcus Altfeld Journal: PLoS Med Date: 2015-11-17 Impact factor: 11.069
Authors: Jean C Digitale; Perri C Callaway; Maureen Martin; George Nelson; Mathias Viard; John Rek; Emmanuel Arinaitwe; Grant Dorsey; Moses Kamya; Mary Carrington; Isabel Rodriguez-Barraquer; Margaret E Feeney Journal: J Infect Dis Date: 2021-07-02 Impact factor: 5.226